background


Product Information:

A-1331852

A-1331852 is a potent BCL-XL-selective inhibitor. BCL-XL is the major antiapoptotic survival protein and may be a novel therapeutic target in CML.

Cat. No.: EX-A1061    Purity: >98%
A-1331852
For research only, Do not use for Human!

SizeUnit Price (US$)StockQuantityOrder
50mg650In-stock
100mg950In-stock
250mg1550In-stock


CAS No.1430844-80-6
Purity>98%
FormulaC38H38N6O3S
Mol Weight658.812
AppearanceSolid powder
SolubilitySoluble in DMSO
Shelf Life>2 years if stored properly
StoragePowder -20℃ 2 years; In solvent -20℃ 1 month;
ShippingShipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
 
 
Reference:  [1]. Leverson JD. Chemical parsing: Dissecting cell dependencies with a toolkit of selective BCL-2 family inhibitors. Mol Cell Oncol. 2015 May 26;3(1):e1050155. doi: 10.1080/23723556.2015.1050155. eCollection 2016 Jan. PubMed PMID: 27308564; PubMed Central PMCID: PMC4845185.

[2]. Lucas CM, Milani M, Butterworth M, Carmell N, Scott LJ, Clark RE, Cohen GM, Varadarajan S. High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia. Leukemia. 2016 Jun;30(6):1273-81. doi: 10.1038/leu.2016.42. Epub 2016 Feb 29. PubMed PMID: 26987906; PubMed Central PMCID: PMC4895185.

[3]. Butterworth M, Pettitt A, Varadarajan S, Cohen GM. BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells. Br J Cancer. 2016 Mar 15;114(6):638-41. doi: 10.1038/bjc.2016.49. Epub 2016 Mar 8. PubMed PMID: 26954718; PubMed Central PMCID: PMC4800304.
CoACoA of A-1331852
Smiles:CC1=C(C=NN1CC12CC3CC(CC(C3)C1)C2)C1=CC=C(N=C1C(O)=O)N1CCC2=C(C1)C(=CC=C2)C(=O)NC1=NC2=CC=CC=C2S1

KEYWORDS: buy A-1331852 | A-1331852 supplier | purchase | cost | manufacturer | order | distributor | buy 1430844-80-6 | 1430844-80-6 supplier